Predominant and novel de novo variants in 29 individuals with ALG13 deficiency: Clinical description, biomarker status, biochemical analysis, and treatment suggestions by Ng, Bobby G. et al.
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1002/jimd.12290 
 
Predominant and novel de novo variants in 29 individuals with ALG13 deficiency: Clinical 
description, biomarker status, biochemical analysis and treatment suggestions. 
 
Bobby G. Ng1, Erik A. Eklund1,2, Sergey A. Shiryaev1, Yin Y. Dong3, Mary-Alice Abbott4, Carla 
Asteggiano5, Michael J. Bamshad6,7, Eileen Barr8, Jonathan A. Bernstein9,10, Shabeed 
Chelakkadan11, John Christodoulou12, 13, Wendy K. Chung14, 15, Michael A. Ciliberto16, Janice 
Cousin17, Fiona Gardiner18, Suman Ghosh19, William D. Graf20, Stephanie Grunewald21, 
Katherine Hammond22, Natalie S. Hauser23, George E. Hoganson24, Kimberly M. Houck25, 
Jennefer N. Kohler9, 26, Eva Morava27, Austin A. Larson28, Pengfei Liu29, 30, Sujana Madathil16, 
Colleen McCormack9, 26, Naomi J.L. Meeks28, Rebecca Miller23, Kristin G. Monaghan31, 
Deborah A. Nickerson7, Timothy Blake Palculict31, Gabriela Magali Papazoglu32 , Beth A. 
Pletcher33, Ingrid E. Scheffer18,,34, Andrea Beatriz Schenone35, Rhonda E. Schnur31, Yue Si31, 
Leah J. Rowe28, Alvaro H. Serrano Russi36, 37, Rossana Sanchez Russo8, Farouq Thabet38, Allysa 
Tuite33, María Mercedes Villanueva35, Raymond Y. Wang39, 40, Richard I. Webster41, 42, Dorcas 
Wilson43, 44, Alice Zalan24, Undiagnosed Diseases Network, University of Washington Center for 
Mendelian Genomics (UW-CMG), Lynne A. Wolfe45, Jill A. Rosenfeld29, 30, Lindsay Rhodes31, 








(1) Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, 
CA 92037, USA. 
 
(2) Lund University, Department of Clinical Sciences, Lund, Pediatrics, Lund, Sweden. 
 
(3) Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DS, 
UK. 
 
(4) Department of Pediatrics, Baystate Children’s Hospital, University of Massachusetts Medical 
School – Baystate, Springfield, MA 01199, USA 
 
(5) CEMECO – CONICET, Children Hospital, School of Medicine, National University of 
Cordoba. Chair of Pharmacology Catholic University of Cordoba, Argentina, Cordoba, 
Argentina. 
 
(6) Department of Pediatrics, University of Washington, Seattle, WA 98195, USA. 
 
(7) Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA. 
 
(8) Department of Human Genetics, Emory University, Atlanta, GA 30322 USA. 
 
(9) Stanford University School of Medicine, Stanford, CA 94305, USA. 
 
This article is protected by copyright. All rights reserved.
(10) Stanford Center for Undiagnosed Diseases, Stanford University, Stanford, CA 94305, USA. 
 
(11) Monash Children’s Hospital, Melbourne, Australia. 
 
(12) Brain and Mitochondrial Research Group, Murdoch Children’s Research Institute, Royal 
Children’s Hospital, Melbourne, and Department of Paediatrics, University of Melbourne, 
Australia.  
 
(13) Discipline of Child & Adolescent Health, Sydney Medical School, University of Sydney, 
Sydney, Australia. 
 
(14) Department of Pediatrics, Columbia University, New York, NY 10027, USA. 
 
(15) Department of Medicine, Columbia University, New York, NY 10027, USA. 
 
(16) Department of Pediatrics, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, 
USA. 
 
(17) Section of Human Biochemical Genetics, National Human Genome Research Institute, 
Bethesda, MD 20892, USA. 
 
(18) University of Melbourne, Austin Health, Melbourne, Australia. 
 
(19) University of Florida College of Medicine, Department of Pediatrics Division of Pediatric 
Neurology, Gainesville, FL 32610, USA. 
 
This article is protected by copyright. All rights reserved.
(20) Division of Pediatric Neurology, Department of Pediatrics; Connecticut Children's; 
University of Connecticut; Farmington, CT 06032, USA. 
 
(21) Metabolic Medicine Department, Great Ormond Street Hospital, Institute of Child Health 
University College London, NIHR Biomedical Research Center, London, UK. 
 
(22) Division of Pediatric Neurology, Department of Pediatrics, University of Alabama at 
Birmingham, Birmingham, AL 35233, USA. 
 
(23) Inova Translational Medicine Institute Division of Medical Genomics Inova Fairfax 
Hospital Falls Church, VA 22042, USA. 
 
(24)  Department of Pediatrics, University of Illinois at Chicago, Chicago, IL 60612, USA. 
 
(25) Department of Pediatrics, Section of Neurology and Developmental Neuroscience, Baylor 
College of Medicine, Houston, TX 77030, USA. 
 
(26) Division of Cardiovascular Medicine, Department of Medicine, Stanford University School 
of Medicine, Stanford, CA 94305, USA. 
 
(27) Department of Clinical Genomics, Mayo Clinic, Rochester, MN 55905, USA. 
 
(28) Section of Clinical Genetics & Metabolism, Department of Pediatrics, University of 
Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA. 
 
(29) Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 
77030, USA. 
This article is protected by copyright. All rights reserved.
 
(30) Baylor Genetics Laboratories, Houston, TX 77030, USA. 
 
(31) GeneDx, Inc. Laboratory, Gaithersburg, MD 20877, USA. 
 
(32) CEMECO – CONICET, Children Hospital, School of Medicine, National University of 
Cordoba, Cordoba, Argentina. 
 
(33) Department of Pediatrics, Rutgers New Jersey Medical School, Newark, NJ 07103, USA. 
 
(34) University of Melbourne, Royal Children’s Hospital, Florey and Murdoch Institutes, 
Melbourne, Australia. 
 
(35) Laboratorio de Neuroquimica "Dr. N. A. Chamoles” - FESEN, Buenos Aires, Argentina. 
 
 
(36) Division of Medical Genetics Children's Hospital Los Angeles, University of Southern 
California, Los Angeles, CA 90027, USA. 
 
(37) Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, 
USA. 
 
(38) MercyOne Pediatric Neurology, Des Moines, IA 50314, USA. 
 
(39) Division of Metabolic Disorders, Children's Hospital of Orange County, Orange, CA 92868, 
USA.  
 
This article is protected by copyright. All rights reserved.
(40) Department of Pediatrics, University of California-Irvine, Orange, CA 92868, USA. 
 
(41) T.Y. Nelson Department of Neurology and Neurosurgery, The Children’s Hospital at 
Westmead, Australia.  
 
(42) Kids Neuroscience Centre, The Children’s Hospital at Westmead, Australia. 
 
(43) Netcare Sunninghill Hospital, Sandton, South Africa.  
 
(44) Nelson Mandela Children's Hospital, Johannesburg, South Africa. 
 
(45) Undiagnosed Diseases Program, Common Fund, National Institutes of Health, Bethesda, 







Hudson H. Freeze 
Professor of Glycobiology, Director, Human Genetics Program 
Sanford Children's Health Research Center 
Sanford-Burnham-Prebys Medical Discovery Institute 
10901 N. Torrey Pines Rd. La Jolla, CA 92037 




Word count for text and summary: Abstract (summary) 200 words, Text 8500 words 
Number of figures and tables: 5 figures, 2 table 














This article is protected by copyright. All rights reserved.
ALG13 encodes a non-redundant, highly conserved, X-linked UDP-N-
Acetylglucosaminyltransferase required for the synthesis of lipid linked oligosaccharide 
precursor and proper N-linked glycosylation. De novo variants in ALG13 underlie a form of early 
infantile epileptic encephalopathy known as EIEE36, but given its essential role in glycosylation, 
it is also considered a congenital disorder of glycosylation, ALG13-CDG. Twenty-four 
previously reported ALG13-CDG cases had de novo variants, but surprisingly, unlike most forms 
of CDG, ALG13-CDG did not show the anticipated glycosylation defects, typically detected by 
altered transferrin glycosylation. Structural homology modeling of two recurrent de novo 
variants, p.A81T and p.N107S, suggests both are likely to impact the function of ALG13. Using 
a corresponding ALG13-deficient yeast strain, we show that expressing yeast ALG13 with either 
of the highly conserved hotspot variants rescues the observed growth defect, but not its 
glycosylation abnormality. We present molecular and clinical data on 29 previously unreported 
individuals with de novo variants in ALG13. This more than doubles the number of known cases. 
A key finding is that a vast majority of the individuals presents with West syndrome, a feature 
shared with other CDG types. Among these, the initial epileptic spasms best responded to ACTH 
or prednisolone, while clobazam and felbamate showed promise for continued epilepsy 
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Novel and recurrent de novo variants in ALG13 cause a neurodevelopmental disorder.  
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Congenital disorders of glycosylation (CDG) are a group of nearly 140 rare metabolic disorders 
which can present with a broad, non-specific spectrum of clinical symptoms. The vast majority 
of CDG are autosomal recessive disorders, but several are caused by de novo variants. One such 
type is ALG13-CDG, which frequently presents as an early infantile epileptic encephalopathy 
(de Ligt et al 2012; Epi KC et al 2013; Michaud et al 2014; Deciphering Developmental 
Disorders 2017; Heyne et al 2019).  
 
Asparagine-Linked Glycosylation 13 Homolog (ALG13) encodes a highly conserved X-linked 
UDP-N-Acetylglucosaminyltransferase required for the transfer of N-Acetylglucosamine 
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(GlcNAc) onto the extending lipid linked oligosaccharide (LLO) structure, dolichol-P-P GlcNAc 
(Bickel et al 2005; Gao et al 2005; Ng and Freeze 2018) (Figure 1A). Studies in yeast show that 
this early step in the LLO synthesis pathway is essential for proper N-linked glycosylation 
(Bickel et al 2005; Gao et al 2005). Given its critical role in N-linked glycosylation, it is not 
surprising that ALG13 and its UDP-GlcNAc transferase activity are conserved across all 
eukaryotic species.  
 
Nearly all our knowledge about the function of ALG13 is based on biochemical and genetic 
analyses in S. cerevisiae. The majority of yALG13 protein localizes to the cytoplasm with only a 
portion in the endoplasmic reticulum (ER) through dimerization with yALG14, an ER 
transmembrane protein (Bickel et al 2005; Gao et al 2005). This ER-localized yALG13 - 
yALG14 heterodimer is essential for both cell viability and proper N-glycosylation, since 
abolishing this interaction results in profound defects in both (Bickel et al 2005; Gao et al 2005; 
Averbeck et al 2007). 
Much less is known about the function of ALG13 in higher eukaryotes, although its strong 
evolutionary conservation would presumably indicate its role in the proper synthesis of LLO.  
 
Within the LLO pathway, at least 35 genes have been identified to cause a glycosylation related 
disorder (Ng and Freeze 2018). To date, 24 individuals have been identified with pathogenic de 
novo variants in ALG13 resulting in a neurodevelopmental disorder primarily characterized by 
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early infantile epileptic encephalopathy (Timal et al 2012; de Ligt et al 2012; Epi KC et al 2013; 
Michaud et al 2014; Smith-Packard et al 2015; Dimassi et al 2016; Kobayashi et al 2016; 
Deciphering Developmental Disorders 2017; Fung et al 2017; Hamici et al 2017; Ortega-Moreno 
et al 2017; Bastaki et al 2018; Galama et al 2018; Heyne et al 2019;; Demos et al 2019; Madaan 
et al 2019). Most of these cases were identified in sequencing studies where clinical and variant 
information is summarized in the supplemental material. Nearly all reported affected persons are 
female and harbor an apparently recurrent de novo variant (c.320G>A; p.N107S). Surprisingly, 
glycosylated serum transferrin, which is a commonly used biomarker for CDG, showed a normal 
glycosylation pattern in the few ALG13-CDG individuals who have been tested (Ng and Freeze 
2018). 
 
Here we present molecular data on 29 individuals with de novo variants in ALG13, including 
three novel variants not yet reported in the literature. Clinical information was available for 26 of 
these individuals, with detailed neurological findings for 24. We address the use of serum 
transferrin as a biomarker and show that two recurrent variants, p.A81T and p.N107S, that affect 
highly conserved residues, impact the function of ALG13 in a yeast complementation assay. 
Molecular modeling shows their potential interactions with the substrate, UDP-GlcNAc.  
 
Methods and Materials 
Clinical data 
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Inclusion criteria for this study required the presence of de novo variants in ALG13 (Genbank 
NM_001099922.2, UniProt Q9NP73). Ultimately, we identified 29 individuals for which 
retrospective clinical data were obtained. Written consent was provided for all families in 
accordance with each individual’s primary physician, neurologist or when required, Sanford 
Burnham Prebys Medical Discovery Institute approval IRB-2014-038-17.  
 
Carbohydrate deficient transferrin analysis  
As previously described (Lacey et al 2001) 
 
Next Generation Sequencing 
Next-generation sequencing (NGS) consisted of either exome sequencing (ES), genome 
sequencing (GS) or targeted gene panels. NGS and analysis was performed via each institutions 
or clinical lab services own standardized method. These methods are available upon request.  
 
ALG13 Structural Modeling 
A structural model of human ALG13 (hALG13) was generated using the Phyre2 server with the 
yALG13 structure (PDB code: 2JZ). MurG is the closest biological ortholog of ALG13/14 for 
which a high-resolution structure is currently available while bound to its substrate UDP-
GlcNAc. Therefore, to get an indication of how UDP-GlcNAc might be positioned in the 
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hALG13 active site, we aligned the structural model of hALG13 with the structure of MurG 
(PDB code: 3S2U) using PyMOL.  
 
Western blot analysis of ALG13 protein 
Fibroblasts from control and affected ALG13 individuals were grown as previously described in 
1g/L glucose DMEM supplemented with 10% heat inactivated FBS (Sigma). Western blot 
analysis was also performed as previously described using a polyclonal antibody to ALG13 
[Proteintech 20810-1-AP] and a monoclonal alpha-tubulin [12G10-DSHB hybridoma bank] 
(Ferreira et al 2018). 
 
Yeast complementation Assay 
Isolation and characterization of a yALG13 mutant strain was previously described (Gao et al 
2005). Survival of this strain is dependent on the expression of wild type yAlg13 protein under 
the control of a GAL1 promoter which is repressed by glucose and induced by galactose. Growth 
assays and carboxypeptidase Y (CPY) glycosylation analysis were both previously described 
(Gao et al 2005; Averbeck et al 2008; Gao et al 2008). The expression plasmid pRS305 
containing yALG13 with a C-terminal 3x FLAG tag driven off a glucose responsive promoter 
was used as a template to introduce either the p.A118T (p.A81T) or p.N144S (p.N107S) yeast 
specific mutants. Insertion of the p.A118T (p.A81T) or p.N144S (p.N107S) mutants was carried 
out using a NEB Q5 site-directed mutagenesis kit.  






Due to the lack of a reliable biomarker for screening and identifying ALG13-CDG, all 
previously reported cases (N=24) were identified via NGS. In our cohort, this trend held true 
with all 29 individuals being identified by NGS (21 ES, 2 GS, 6 gene panel) (Table 1). We 
identified two recurrent de novo variants that accounted for the majority of identified individuals. 
The c.241G>A [p.A81T] variant was observed in 3/29 (10%) individuals, while the c.320A>G 
[p.N107S] variant was observed in the vast majority 23/29 (79%) (Figure 1B, Table 1). The 
c.320A>G [p.N107S] variant was also the most frequent (22/24 (92%) in previously reported 
cases (Figure 1B). We also identified several novel de novo variants including c.50T>A 
(p.I17N), c.207_209delAGA (p.E69del) and c.2915G>T (p.G972V) (Figure 1B, Table 1). None 
of the mentioned variants included in this cohort are present in gnomAD v2.1.1 or v3 (accessed 
2020.5.20). In silico modeling each specific variant was performed using the combined 
annotation dependent depletion (CADD; http://cadd.gs.washington.edu/) scoring method and 
showed each variant to have a score above 20 [p.I17N (25.7), p.A81T (25.3), p.N107S (20.7), 
p.G972V (27)] placing all five in the top 1% of deleterious variants in the human genome. 
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Clinical Phenotype 
ALG13 deficiency presents primarily as a neurodevelopmental disorder of varying severity. In 
our cohort, we were able to review clinical records for 26 individuals and found the most 
frequently seen symptoms were developmental delays in 26/26 (100%), seizures/epilepsy in 
24/26 (92%), intellectual disability in 22/24 (92%) who could be assessed for this feature, and 
hypotonia in 22/26 (85%) (Figure 2).  
Due to the severe epileptic encephalopathy previously reported in this disease, a more in-depth 
analysis of the epileptic manifestations was performed in those individuals (n=24) for whom 
detailed information was available. In the 24 individuals who presented with seizures, the mean 
age of onset was 6.5 (CI 4.3 - 8.7) months. The semiology was very consistent, with epileptic 
spasms (ES) in 20/23 (87%) individuals as the presenting semiology, and hypsarrhythmia as the 
initial EEG finding in 20/23 (87%) individuals with recorded initial EEG changes (Table 2). The 
spasms were treated either with adrenocorticotropic hormone (ACTH), prednisolone (Pred) or 
vigabatrin (VGB). ACTH and/or Pred was described as an effective treatment for ES in eleven 
individuals, and ineffective in five individuals, whereas VGB was effective in five individuals 
and was ineffective, or sometimes even aggravated seizure activity, in four individuals. One 
subject showed VGB-induced changes on brain MRI scan symmetrical diffusion restriction in 
the thalamus and globus pallidus), which reversed once VGB was discontinued. A plethora of 
anti-seizure medications was used, illuminating the pronounced pharmaco-resistance of this 
disorder. Benzodiazepines (clobazam (CLB), clonazepam, nitrazepam seemed effective in a 
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rather high proportion of individuals (5/8-63%) where the most commonly used was CLB (used 
in 7/8-88%) (Table 2). Felbamate (FBM) was only used in two individuals but was reported to 
be effective in both. Topiramate was used more frequently (7 individuals), however, none of the 
affected individuals had a favorable outcome with this treatment. Levetiracetam, valproate and 
lamotrigine showed a minimal effectiveness, with a reported positive effect in 2/8, 1/7 and 1/6 
individuals, respectively. Cannabidiol was used in five subjects of whom two had a positive 
response. Most individuals continued to show signs of an epileptic encephalopathy after the 
initial spasms were treated. In six individuals, a diagnosis of Lennox-Gastaut syndrome (LGS) 
was made following the initial diagnosis of infantile spasms (IS). Five individuals remain 
seizure-free on current treatment. In addition to pharmaceuticals, a ketogenic diet (KD) was 
widely used in our cohort (12/23-52%); eight had a sustained positive effect of the diet and one 
had an initial response (Table 2). Two individuals had placement of a vagus nerve stimulator 
(VNS), only one of which had a favorable response. All individuals had an MRI scan, but no 
consistent findings were observed. Most were either normal or had nonspecific and vaguely 
described findings such as cerebral atrophy and benign enlargement of the subarachnoid spaces 
(Table 2). No structural abnormalities or dysplasias have been reported as potential 
epileptogenic foci. 
 
In addition to characterizing the prominent neurological phenotype, we queried other clinical 
symptoms occurring in these subjects.  
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In our cohort, ocular deficits were noted in 12/26 (46%) with cortical visual impairment present 
in eight of those individuals (Figure 2). Gastrointestinal symptoms characterized by either 
vomiting, GERD, reflux and the need for G-tube placement were seen in 11/26 (42%). Skeletal 
defects, primarily scoliosis (6/11) or osteopenia (2/11), were seen in a total of 11/26 (42%) 
individuals. Dysmorphic features, mainly facial were seen in 11/26 (42%) and included coarse 
features, high arched palate or prominent forehead to name a few (Figure 2). Cardiac (6/26), 
respiratory (5/26) and immunologic abnormalities (5/26) were all seen in < 25% of cases (Figure 
2).  
 
Out of the group of individuals carrying p.N107S variant, three individuals (CDG-0078, 0081 
and 0135) were not included in the final clinical summary. CDG-0078 and CDG-0077 are 
identical twins and both carry the de novo p.N107S. However, in contrast to her affected sister, 
CDG-0078 does not have any clinical history of developmental and intellectual delays or seizure 
activity and is considered to be “unaffected.” One explanation for the dramatic clinical 
discrepancy between these two identical sisters is skewed X-inactivation of mutant ALG13 in the 
“healthy” sister. However, no additional testing could be performed. For CDG-0081, we were 
not able to obtain a complete clinical history, although it is known that she had intractable 
seizures and, at 13 years of age, is the only individual in our cohort who has died (Figure 2). 
Finally, for CDG-0135, we were only provided variant information for reporting. 
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We did not see a consistent ALG13-CDG-specific phenotype that could be used to help 
differentiate this disorder from other CDG types or even other epilepsy-related disorders. This 
highlights the importance of finding an ALG13-CDG-specific biomarker. 
 
Carbohydrate deficient transferrin (CDT) analysis  
ALG13 is a critical component of the N-linked glycosylation pathway and it is logical to use 
carbohydrate deficient transferrin (CDT) analysis as a biomarker since the great majority of N-
linked defects have an abnormal CDT. However, it was previously noted that several affected 
females who carried the recurrent p.N107S variant were tested and found to have a normal CDT 
result, indicating normal N-linked glycosylation, at least in hepatocytes (Smith-Packard et al 
2015). In our cohort of 29 individuals, 14 had CDT testing with 14/14 (100%) found to be 
normal (Figure 2). Two individuals (CDG-0417, CDG-1017) were found to have a CDT profile 
suggestive of a type I CDG. CDG-0417 had two mildly abnormal CDT results detected by 
capillary zone electrophoresis (initial CDT at age 1yr-11mon). However, we should note that 
over the course of a month, this amount of this abnormal peak improved for no clear reason. A 
follow up analysis four years later using the more sensitive liquid chromatography mass 
spectrometry method showed that the abnormal peak was still detectable, but it was within the 
normal reference range. CDG-1017 also had a detectable abnormal peak (initial CDT at age 8yr-
10mon) suggesting a type I pattern and, like CDG-0417, the amount was within the normal 
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reference range. While only 14/29 individuals had CDT analysis performed, it is encouraging 
that CDG was considered as a possible cause in nearly half the subjects. These data suggest that 
CDT is unlikely to be a reliable biomarker for ALG13-CDG caused by de novo variants, and 
further work will be needed to identify one. 
 
ALG13 Structural Modeling 
The protein structure for S. cerevisiae yALG13 and the Pseudomonas aeruginosa ALG13 
ortholog, MurG, are both known (Hu et al 2003; Wang et al 2008). MurG is a single polypeptide 
whose N-terminal domain has a high degree of homology to ALG14 and a C-terminal domain to 
ALG13 (Gao et al 2008). Furthermore, MurG is required to carry out a similar enzymatic 
reaction as the human ALG13:ALG14 heterodimer. Due to the structural conservation of 
yALG13 and MurG to human ALG13, we aimed to model and then determine the potential 
impact the p.A81T and p.N107S variants may have on human ALG13 protein.  
 
From this alignment, human p.A81 and p.N107 are both situated close to the predicted position 
of the GlcNAc moiety of UDP-GlcNAc, the donor substrate (Figure 3A, Figure 3B). The 
p.N107 in human ALG13 is predicted to be positioned close to the homologous p.Q288 in P. 
aeruginosa MurG (Brown et al 2013) (Figure 3B), which hydrogen bonds with the C3 hydroxyl 
group, and is part of the DDHQ motif that is homologous to the NNHQ motif in human ALG13. 
The p.A81 in human ALG13 is homologous to p.A260 in P. aeruginosa MurG, which is part of a 
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hydrogen bond network with p.N291 and p.A125, that could be important in the correct 
positioning of p.N124, which binds to the C4 and C6 hydroxyls of the GlcNAc moiety. Further 
enzymatic and biophysical analyses are needed to determine the roles that p.N107 and p.A81 
play in human ALG13 function, as well as how the disease-causing mutations affect this. 
Hence, significant changes to the side chain chemistry of either of these residues is likely to 
affect the structure of the ALG13 active site. We speculate these variants could affect their 
affinity and /or specificity for the activated monosaccharide carried by the UDP. What is clear is 
that neither the p.A81T nor the p.N107S variants affect the stability of mutant ALG13 protein 
(Figure 4). 
 
Yeast complementation Assay 
Deletion of yALG13 causes a severe growth defect and ultimately lethality 
(https://www.yeastgenome.org/locus/S000003015). A conditional null mutant yALG13 strain is 
available, but its survival depends on the presence of wild type yALG13 driven off a GAL1-
responsive promoter (i.e. when galactose is provided in the absence of glucose, the strain will 
grow). We took advantage of a previously described method using this mutant strain and the 
ability to express yALG13 under the control of a glucose responsive promoter (Gao et al 2005). 
When we expressed highly conserved equivalent yALG13 mutants and shifted to selection under 
glucose (i.e. the rescued yALG13 under galactose is repressed), the p.A118T and p.N144S 
mutants both rescued the growth defect in a similar fashion to wild type (Figure 5). However, 
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unlike wild type yALG13, neither the p.A118T nor p.N144S mutants were capable of restoring 
glycosylation of a commonly used biomarker (carboxypeptidase Y, CPY) for yeast glycosylation 
mutants (Figure 5) (Avaro et al 2002). Importantly, Western blot analysis determined neither 
expressed mutation affected the stability of yALG13 when compared to wild type (Figure 5). 




Here we present data on 29 newly reported individuals who were found to have de novo variants 
in ALG13, which more than doubles the number of known cases. Previously de novo variants in 
ALG13 were shown to cause a neurodevelopmental disorder characterized by varying degrees of 
developmental and intellectual disabilities and epilepsy. Together with our novel cases, the total 
number of individuals affected with ALG13-CDG who have been identified is now 53.  
The epileptic phenotype in the ALG13-CDG subjects described here is strikingly homogenous 
and is consistent with previous publications (Fung et al 2017; Ortega-Moreno et al 2017; Madaan 
et al 2019). It emerges in the usual time for ES, with a mean age of 6.5 months at the debut of the 
seizures, where the peak age at the debut of spasms in the whole group is 6-8 months (Riikonen 
2001). Most individuals show the electrophysiological pattern of hypsarrhythmia in their first 
EEG, and all show developmental arrest, thus fulfilling the criteria for West syndrome. This age- 
dependent epileptic encephalopathy syndrome often develops later on into another age-
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dependent syndrome, LGS, and many of the individuals in our cohort displayed a fully 
developed LGS or partial symptoms thereof (Lombroso 1983). Only five individuals remained 
seizure-free on treatment. Traditionally, three main treatment approaches to ES exist, 
corticosteroids (usually Pred or ACTH), and the GABA aminotransferase inhibitor VGB 
(γ−vinyl-GABA). In a recent review of all clinical studies involving these agents, ACTH seems 
to be the most effective single treatment, whereas a combination of VGB and ACTH also shows 
promise (Riikonen 2020). In our cohort ACTH and Pred seemed superior to VGB in both 
effectiveness and side-effects, which is also supported by previous case descriptions (Epi KC et 
al 2013; Kobayashi et al 2016; Madaan et al 2019). We therefore suggest that ACTH or Pred to 
be used as the first line treatment of ALG13-related ES, possibly with an extended period of 
weaning as several individuals had seizure recurrence during tapering. In the continued care for 
these individuals, a large number of different AEDs have been used in our cohort, highlighting 
widespread pharmaco-resistance.  
 
Amongst the different drugs, two stood out as potentially favorable alternatives, benzodiazepines 
(most commonly CLB) and FBM). FBM is a drug initially approved for LGS that was previously 
restricted due to unusual cases of fatal aplastic anemia and hepatic failure (Shah et al 2016), but 
now is seeing a revival as a rescue agent in unresponsive IS (Dozieres-Puyravel et al 2020); its 
use in ALG13-related epileptic encephalopathy should certainly be further studied. A KD is a 
powerful treatment option in some epileptic encephalopathies such as Dravet syndrome (Dressler 
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et al 2015), and other metabolic conditions such as GLUT1-deficiency (Kass et al 2016). In 
ALG13-CDG with epileptic encephalopathy, we only found one report of successful treatment 
using a KD (Smith-Packard et al 2015), and it is unclear from the other reports whether it has 
been tried on this cohort of individuals. In our cohort, however, as many as 12 individuals were 
being treated with, or were previously treated with a KD; eight showed a sustainable response, 
whereas one showed an initial response to the diet. This is very encouraging and suggest a KD 
may be an important potential alternative/complement to pharmaceuticals in this disease. 
 
One important issue we were not able to fully address was the role X-chromosome inactivation 
(XCI) plays in ALG13 deficiency. In our cohort, only three individuals were reported to have 
XCI analysis and all were found to have random XCI from whole blood samples. Because of the 
strong neurological phenotype, XCI in whole blood may not fully represent what is happening in 
the brain. 
Despite the clear role of ALG13 in glycosylation, the common CDG biomarker transferrin was 
not as reliable for ALG13-CDG as it is for other CDG types. This is reminiscent of SLC35A2-
CDG, which is also an X-linked disorder caused by de novo variants and like ALG13-CDG can 
give unreliable or unexpected CDT results. However, unlike SLC35A2-CDG, which is due to 
loss of function variants, we hypothesize that the recurrent p.N107S and other de novo variants 
are likely gain of function variants. While it is unclear what that gain of function is, this could 
potentially explain why CDT is not abnormal.  
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As is the case with all LLO synthesis proteins, ALG13 is an essential component of the 
glycosylation machinery. In both yeast and humans, it is the only known enzyme capable of 
carrying out the transfer of a GlcNAc onto Dol-P-P-GlcNAc to generate Dol-P-P-GlcNAc-
GlcNAc, which serves as a substrate for ALG1, the next enzyme in LLO biosynthesis (Figure 
1A). Human deficiencies in ALG13 should cause a profound glycosylation defect like that seen 
in the preceding (DPAGT1-CDG) and subsequent (ALG1-CDG) LLO steps (Ng et al 2019; Ng 
et al 2016). However, despite the proven role of ALG13 in glycosylation, individuals with de 
novo variants do not demonstrate a clear glycosylation abnormality, at least not in serum 
glycoproteins or skin fibroblasts (data not shown). Interestingly, this is also true for the ALG13 
specific binding partner, ALG14, where biallelic variants cause both congenital myasthenic 
syndrome-15 (ALG14-CMS) and also a disorder characterized as an early lethal 
neurodegeneration with myasthenic and myopathic features (Cossins et al 2013; Schorling et al 
2017). 
 
While ALG13 and ALG14 are both ubiquitously expressed proteins, it is possible that 
deficiencies in either could cause a tissue-specific disorder. This has for example been seen with 
a few CDG types that primarily affect the liver (e.g. MPI-CDG, TMEM199-CDG, CDCC115-
CDG, ATP6AP1-CDG) (Marques-Da-Silva et al 2017). 
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While ALG13’s role in N-glycosylation has been well documented in yeast, its role in humans is 
less clear and more complicated because, at some point within its evolution from S. cerevisiae to 
H. sapiens, there was a dramatic change in the ALG13 protein. S. cerevisiae ALG13 (Uniprot 
P53178) is a small 202 amino acid (aa) protein consisting only of a glycosyltransferase 28 
(GT28) domain. However, in humans, multiple transcripts of ALG13 (Uniprot Q9NP73) occur 
with the canonical transcripts encoding a 1137aa protein, two intermediate forms of 1059aa and 
954aa, and the smallest form of 165aa. This smaller 165aa form most closely resembles the 
single, essential yeast protein. Interestingly, the canonical human isoform contains not only the 
glycosyltransferase 28 domain, but also several other domains including an OTU deubiquitinase 
domain (OTUD), a TUDOR domain and a Proline rich domain (Figure 1B).  
 
Transcript 3 lacks 78 amino acid of the N-terminal GT28 domain just before the p.A81T hotspot, 
while transcript 4 lacks 105 amino acid of the N-terminal GT28 domain prior to the p.N107S 
hotspot. (Figure 1B). Both of these proteins likely lack GT28 activity due to the loss of many 
critical amino acids required for substrate binding and catalytic activity. We are able to detect 
three of four isoforms (Figure 4); however, it is very possible isoform 4 is not detectable due to 
the loss of the antibody epitope.  
 
It is unclear what roles the different transcripts play in the pathology of ALG13 deficiency. We 
hypothesis that only the long and short forms could potentially harbor a functional GT28 
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domain, but to date no functional studies have proven the long form has catalytic activity. Thus, 
it is unclear if the long and short forms compensate for one another. Studies have shown it is 
possible to completely delete the long isoform form, but not the short form, suggesting the short 
form is the essential glycosyltransferase required for glycosylation (Gao et al 2019). 
 
The functional significance of these additional domains within ALG13 is unknown. These other, 
non-glycosyltransferase domains are found together as a separate gene in zebrafish 
(https://zfin.org). In zebrafish, zgc:92907 is most similar to the small ALG13 isoform seen across 
all organisms, while the gene annotate as ALG13 does not contain the GT28 domain required for 
GT28 activity but does contain the OTUD family domain. It is unclear when during evolution 
these quite different genes fused into the single gene seen in humans and other vertebrates. 
 
It is tantalizing to speculate what functions these additional domains within the long isoform of 
ALG13 are performing. For example, the ovarian tumor deubiquitinase (OTUD) family domain 
of ALG13 contains the conserved catalytic triad of amino acids (Asp239, Cys242, His345) 
required for deubiquitinase DUB activity (Mevissen et al 2013). However, when expressed in 
bacteria, the purified ALG13 OTUD domain lacked DUB activity towards a Ub propargylamide 
(Ub-PA) substrate but did have activity toward an artificial haloalkyl substrate (Mevissen et al 
2013). Is it possible that ALG13-dependent DUB activity is restricted to a very small select set 
of protein targets, like those in the LLO pathway? Interestingly, DPAGT1, which catalyzes the 
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proceeding step to ALG13, has been found to be ubiquitinated at Lys48 within a critical 
cytoplasmic loop required for UDP-GlcNAc binding (Udeshi et al 2013). Could the long isoform 
of ALG13 DUB activity regulate DPAGT1 activity via deubiquitination? These, and many other 
questions remain unanswered about the function of ALG13. 
 
In conclusion, we present data on 29 individuals found to specifically harbor de novo variants in 
ALG13, allowing us to expand both the clinical phenotype and molecular understanding of this 
disorder. Clinical and pharmacological data suggest certain anti-seizure medications could 
potentially be prioritized as a first line therapies, while others could be avoided. Furthermore, 
non-pharmaceutical alternatives such as a KD could have beneficial effects on suppression of 
seizures and should be considered. We identified several novel de novo variants, additional cases 
of the recurrent p.N107S and p.A81T. Structural modeling predicts both the p.A81T and 
p.N107S variants may affect the ALG13 active site and UDP-GlcNAc interface. Finally, we 
show expression of either recurrent variant in an ALG13 mutant yeast model restores the 
observed growth defect but does not correct the N-glycosylation abnormality, suggesting that 
both residues are important for normal glycosylation in yeast.  
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Figure Legend 
Figure 1 – Lipid linked oligosaccharide pathway highlighting the role of ALG13 and a 
schematic showing the location of de novo variants identified in ALG13 (A) Schematic 
showing the role of ALG13 in LLO synthesis. (B) Schematic showing the four primary ALG13 
transcripts with the positions of each de novo variant within the ALG13 protein. Variants 
identified in this study have been placed on the top portion, while previously reported variants 
are on the lower portion. The number of individuals identified is also listed as (n=). The solid 
triangles denote the catalytic triad required for the deubiquitinase domain active site D239, 
C242, H345. 
 
Figure 2 – Clinical summary for 26 individuals with de novo variants in ALG13. General 
clinical summary for 26 individuals found to have de novo variants in ALG13. 
 
Figure 3 – Structural homology model of ALG13, showing the predicted positions of 
recurrent de novo mutations relative to UDP-GlcNAc. (A) N107, A81 and UDP-GlcNAc 
shown as sticks, colored according to the element, with carbon represented in yellow in UDP-
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GlcNAc and mauve in ALG13. Structural elements of ALG13 labelled according to (Wang et al 
2008). (B) shows an overlay of ALG13 in mauve, and MurG (PDB: 3S2U, PMID: 22973843) in 
grey, with H-bonds observed in the structure represented by dashed black lines. 
 
Figure 4 – Western blot analysis of ALG13 from fibroblasts. Available fibroblasts were used 
for whole cell extracts to detect endogenous ALG13 protein levels. Alpha tubulin was used as a 
loading control to assure equal protein levels.  
 
Figure 5 – Yeast complementation assay using an ALG13 deficient yeast strain. 
(A) An ALG13 deficient yeast strain was grown under selection conditions allowing for 
expression of wild type yALG13 when grown in the presence of galactose. Transfection and 
expression of various yALG13 mutants were performed as previously described (Gao et al 
2005). (B) Western blot analysis of glycosylated carboxypeptidase Y under various 
complementation and growth conditions was performed in triplicates with representative data 
shown. (C) Western blot analysis showing the transfected levels of yALG13-Flag tagged protein. 
 
Table 1 – Genotypes identified in 29 individuals found to have de novo variants in ALG13. 
Genotypes from 29 individuals along with their sex, inheritance status, ALG13 variant and the 
method of detection are listed. Nucleotide numbering for cDNA uses +1 as the A of the ATG 
translation initiation codon in the reference sequence (Genbank: NM_001099922.2, UniProt: 
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Q9NP73), with the initiation codon as codon 1. 
 
Table 2 – Neurological summary for 42 individuals with de novo variants in ALG13 
Detailed neurological summary for 25 individuals in our cohort found to have de novo variants in 
ALG13. Additionally, available information for 17 previously reported individuals is also 
provided. Bolded drugs indicate a favorable response effect, non-bolded ones indicate uncertain 
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Table 1 – Genotypes identified in 29 individuals with de novo variants in ALG13. 
 





1 CDG - 0075 Affected F de novo c.320A>G p.N107S Panel 
2 CDG - 0077* Affected F de novo c.320A>G p.N107S Panel 
3 CDG - 0078* Unaffected F de novo c.320A>G p.N107S Panel 
4 CDG - 0079 Affected F de novo c.320A>G p.N107S ES 
5 CDG - 0080 Affected F de novo c.320A>G p.N107S ES 
6 CDG - 0081 Affected F de novo c.320A>G p.N107S ES 
7 CDG - 0082 Affected F de novo c.320A>G p.N107S GS 
8 CDG - 0083 Affected M de novo c.320A>G p.N107S ES 
9 CDG - 0085 Affected F de novo c.241G>A p.A81T Panel 
10 CDG - 0086 Affected F de novo c.320A>G p.N107S Panel 
11 CDG - 0088 Affected F de novo c.320A>G p.N107S ES 
12 CDG - 0089 Affected F de novo c.241G>A p.A81T ES 
13 CDG - 0092 Affected F de novo c.320A>G p.N107S Panel 
14 CDG - 0101** Affected M de novo c.2915 G>T p.G972V ES 
15 CDG - 0125 Affected F de novo c.320A>G p.N107S ES 
16 CDG - 0133 Affected F de novo c.320A>G p.N107S ES 
17 CDG - 0134 Affected F de novo c.320A>G p.N107S ES 
18 CDG - 0135 Affected F de novo c.320A>G p.N107S ES 
19 CDG - 0136 Affected F de novo c.320A>G p.N107S ES 
20 CDG - 0139 Affected F de novo c.320A>G p.N107S ES 
21 CDG - 0140** Affected F de novo c.320A>G p.N107S ES 
22 CDG - 0141 Affected F de novo c.320A>G p.N107S ES 
23 CDG - 0417 Affected F de novo c.241G>A p.A81T ES 
24 CDG - 0431 Affected F de novo c.320A>G p.N107S GS 
25 CDG - 0453 Affected F de novo c.50T>A p.I17N ES 
26 CDG - 0456 Affected F de novo c.320A>G p.N107S ES 
27 CDG - 0457 Affected F de novo c.207_209del AGA p.E69del ES 
28 CDG - 0458 Affected F de novo c.320A>G p.N107S ES 
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29 CDG - 1017 Affected F de novo c.320A>G p.N107S ES 
 
  *CDG - 0077 and CDG - 0078 are identical twins 
**CDG - 0101 and CDG - 0140 were found to be mosaic. 
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Table 2 – Neurological summary for 42 individuals with de novo variants in ALG13 
 
 
Case Sex Mutation 














CDG-0075 F p.N107S 6 months GTCS Mu/G normal VPA no N/A yes 
CDG-0077 F p.N107S 10 months IS H BESS 
ACTH, VGB, LEV, 
TPM no N/A yes 
CDG-0079 F p.N107S 6 months IS H normal 
ACTH, LEV, ESX, 




CDG-0080 F p.N107S 3 months IS H normal ACTH, Pred, VGB, B6 no Poor yes 
CDG-0082 F p.N107S 6 months IS H lack of WM 
Pred, VGB, ACTH, 
LEV, VPA, ZON, LCM, 
CBD, NZM Keto N/A yes 
CDG-0083 M p.N107S 7 months IS H 
cerebral 
atrophy 
ACTH, VGB, VPA, 
ESX, CLB, LTG Keto 
 Frontal lobe 
sz/Nocturnal 
sz. yes 
CDG-0085 F p.A81T 9 months IS H normal ACTH no 
sz free w/o 
AED yes 
CDG-0086 F p.N107S 2 months IS? H? BESS/normal 
ZON, LTG, RUF, LEV, 





CDG-0088 F p.N107S 6 months IS H VGB changes 
VGB, TPM, ACTH, 
FBM, Pred no N/A yes 
CDG-0089 F p.A81T 1 month IS H 
BESS, 
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CDG-0092 F p.N107S 1 month IS H normal 
ACTH, Pred, B6, VGB, 






CDG-0125 F p.N107S 4-5 months IS H 
mild cerebral 
atrophy 
CBD, CLB, CZP, LEV, 
Pred, LCM no N/A yes 
CDG-0133 F p.N107S no sz no normal normal N/A N/A N/A yes 
CDG-0134 F p.N107S 4 months IS H normal Pred, VGB no 
sz free w/o 
AED yes 
CDG-0136 F p.N107S 3 months IS H PVL 
VPA, TPM, CZP, CLB, 
LEV, NZM, LTG, ESX, 
PHB VNS, Keto LGS yes 
CDG-0139 F p.N107S 5 months IS H normal Pred, CZP, B6, VGB Keto 
sz free on 
Keto yes 
CDG-0140 F p.N107S 18 months ES H normal ZON, LEV no GC yes 
CDG-0141 F p.N107S 6 months N/A N/A 
cortical 




CDG-0417 F p.A81T 1 month IS H 
progressive 
atrophy 
Pred, VGB, LEV, CLB, 





CDG-0431 F p.N107S 5 months IS H 
mild cerebral 
atrophy 
ACTH, CLB, LEV, 
TPM, LTG, OXC Keto N/A yes 
CDG-0453 F p.I17N 10 months 
Eye 
deviation Mu normal LEV, CLB, CBD VNS 
LGS, sz free 
on treatment yes 
CDG-0456 F p.N107S 6 months 
absence w 
eye flutter Fo BESS PHB, TPM, ACTH Keto 
M/GT, sz 
free on keto yes 
CDG-0457 F p.E69del 24 months IS 
evolving 
H normal VGB, VPA, FBM no LGS yes 
CDG-0458 F p.N107S 6 months IS H 
cerebral 
atrophy 
Pred, VGB, ACTH, 
ZON, CBD Keto 
LGS, 
refractory yes 
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CDG-1017 F p.N107S 7 months IS H normal ACTH, LEV, LTG Keto 
Complex 
partial sz yes 
Madaan et 
al., 2019 F p.N107S 5 months IS H normal ACTH no infrequent sz yes 
Fung et al., 






al., 2017 F p.N107S 5 months IS N/A N/A N/A N/A LGS N/A 
Bastaki et 
al., 2018 F p.N107S N/A IS H N/A N/A N/A N/A yes 
Galama et 
al., 2018 M p.N107S 4.5 months IS H 
hypoplasia of 
CC/DM 
VGB, Pred, VPA, NZM, 
LTG, LEV no 
Pred stopped 
ES; LEV 
stable GTCS yes 
DDD 
Study, 2017 F p.N107S N/A N/A N/A N/A N/A N/A Sz yes 
DDD 
Study, 2017 F p.N107S N/A N/A N/A N/A N/A N/A Sz yes 
Hamici et 
al., 2017 F p.N107S N/A IS H N/A N/A N/A N/A yes 
Epi4K 
Consortium, 
2016 F p.N107S 1-2 months Tonic/IS H VGB changes 
VGB, Pred, TPM, LEV, 






et al., 2016 F p.N107S 6 months IS H 
cerebral 
atrophy ACTH N/A 
Reduced sz 
on ACTH yes 
Dimassi et 
al., 2016 F p.N107S 2 months IS H 
mild global 





al., 2015 F p.N107S 8 months IS H N/A ACTH Keto 
Complex 
partial sz at 
5 yrs severe 
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Michaud et 
al., 2014 F p.N107S 4 months IS H 
cerebral 












2013 F p.N107S 4 months IS H normal N/A N/A LGS severe 
de Ligt et 
al., 2012 F p.N107S N/A N/A N/A 
atrophy, 
delayed 





Timal et al., 




Abbreviations: ACTH, adrenocorticotropic hormone; B6, pyridoxine; BESS, benign enlargement of the subarachnoidal spaces; CBD, 
cannabidiol; CC, corpus callosum; CLB, clobazam; CZP, clonazepam; DM, delayed myelinization; ESX, ethosuximide; FBM, 
felbamate; Fo, focal; GTCS, generalized tonic-clonic seizure; GBP, gabapentin; H, hypsarrhythmia; IS, infantile spasms; LCM, 
lacosamide; LGS, Lennox-Gastaut syndrome; LEV, levetiracetam; LTG, lamotrigine; Keto, ketogenic diet; Mu, multifocal; NZM, 
nitrazepam OXC, oxcarbazepine; PHB, phenobarbital; Pred, prednisolone; PVL, Periventricular leukomalacia; RUF, rufinamide; SZ, 
seizure; TPM, topiramate; VGB, vigabatrin, VNS, vagus nerve stimulator; VPA, valproate; WM, white matter; ZON, zonisamide. 
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Clinical Summary of 26 ALG13-CDG Individuals
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